Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 15, 2008

Charles River Opens Preclinical Site in Shanghai

  • Charles River Laboratories has opened a 60,000 sq. ft. preclinical facility in Shanghai. The site is expected to provide GLP services in the first quarter of 2009.

    Through this facility, Charles River will help multinationals and local biopharmaceutical organizations accelerate their drug development programs in China. Services provided will comply with regulatory agencies including the Association for Assessment and Accreditation of Laboratory Animal Care, Canadian Council on Animal Care, China’s State Food and Drug Administration, Organization for Economic Cooperation and Development, and FDA.

    “As our clients make their initial forays into China, we are creating a center of excellence that embodies global best practices alongside them,” notes James C. Foster, president, chairman, and CEO. “The same high standards of research, safety, humane care, and good laboratory practices that globally distinguish Charles River are replicated in our Shanghai facility.”

    This facility is a result of a joint venture inked in March 2007 with Shanghai BioExplorer. Charles River Preclinical Services Greater China was thus formed, which is majority-owned and controlled by Charles River.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »